Published in Mol Cancer on May 28, 2012
Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol (2015) 1.48
Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer. Br J Cancer (2013) 0.98
Overview of a chemoresponse assay in ovarian cancer. Clin Transl Oncol (2014) 0.96
Transforming growth Factor-Beta-Induced Protein (TGFBI)/(βig-H3): a matrix protein with dual functions in ovarian cancer. Int J Mol Sci (2012) 0.93
Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer. PLoS One (2012) 0.92
Tumor suppressor genes and their underlying interactions in paclitaxel resistance in cancer therapy. Cancer Cell Int (2016) 0.87
High-level β1-integrin expression in a subpopulation of highly tumorigenic oral cancer cells. Clin Oral Investig (2013) 0.82
Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma. Oncotarget (2016) 0.80
Gallotannin imposes S phase arrest in breast cancer cells and suppresses the growth of triple-negative tumors in vivo. PLoS One (2014) 0.79
ADAM17 Promotes Motility, Invasion, and Sprouting of Lymphatic Endothelial Cells. PLoS One (2015) 0.78
Lysosomal trafficking of TGFBIp via caveolae-mediated endocytosis. PLoS One (2015) 0.77
Discoidin domain receptor 1 contributes to tumorigenesis through modulation of TGFBI expression. PLoS One (2014) 0.77
Largescale Transcriptomics Analysis Suggests Over-Expression of BGH3, MMP9 and PDIA3 in Oral Squamous Cell Carcinoma. PLoS One (2016) 0.77
SPARC Regulates Transforming Growth Factor Beta Induced (TGFBI) Extracellular Matrix Deposition and Paclitaxel Response in Ovarian Cancer Cells. PLoS One (2016) 0.77
The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer. Int J Mol Sci (2017) 0.75
Integrin signaling. Science (1999) 16.44
Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature (1984) 14.25
Interactions between cancer stem cells and their niche govern metastatic colonization. Nature (2011) 6.94
Variants of the cell recognition site of fibronectin that retain attachment-promoting activity. Proc Natl Acad Sci U S A (1984) 5.13
Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J Bone Miner Res (1999) 4.68
Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res (2002) 3.64
Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell (2004) 3.63
Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J (1993) 3.43
Synergistic control of cell adhesion by integrins and syndecans. Nat Rev Mol Cell Biol (2007) 3.21
Signal co-operation between integrins and other receptor systems. Biochem J (2009) 2.59
Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway. Oncogene (2006) 2.36
The fibronectin-binding integrins alpha5beta1 and alphavbeta3 differentially modulate RhoA-GTP loading, organization of cell matrix adhesions, and fibronectin fibrillogenesis. J Cell Biol (2002) 2.14
Chromosomal instability determines taxane response. Proc Natl Acad Sci U S A (2009) 2.12
The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell (2007) 2.05
Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev (2008) 2.00
beta ig-h3: a transforming growth factor-beta-responsive gene encoding a secreted protein that inhibits cell attachment in vitro and suppresses the growth of CHO cells in nude mice. DNA Cell Biol (1994) 1.97
Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene (2001) 1.96
The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells. J Cell Biol (2004) 1.91
Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res (2005) 1.86
Identification of motifs for cell adhesion within the repeated domains of transforming growth factor-beta-induced gene, betaig-h3. J Biol Chem (2000) 1.82
Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell (2003) 1.81
Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res (2001) 1.64
Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol (1999) 1.64
Identification of motifs in the fasciclin domains of the transforming growth factor-beta-induced matrix protein betaig-h3 that interact with the alphavbeta5 integrin. J Biol Chem (2002) 1.53
TGFBIp/betaig-h3 protein: a versatile matrix molecule induced by TGF-beta. Int J Biochem Cell Biol (2007) 1.51
Modulating microtubule stability enhances the cytotoxic response of cancer cells to Paclitaxel. Cancer Res (2011) 1.37
Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer. Gynecol Oncol (1995) 1.35
The transforming growth factor-beta-inducible matrix protein (beta)ig-h3 interacts with fibronectin. J Biol Chem (2002) 1.35
TGFBI deficiency predisposes mice to spontaneous tumor development. Cancer Res (2009) 1.34
Characterization of a cartilage-derived 66-kDa protein (RGD-CAP/beta ig-h3) that binds to collagen. Biochim Biophys Acta (1997) 1.33
Identification of the alphavbeta3 integrin-interacting motif of betaig-h3 and its anti-angiogenic effect. J Biol Chem (2003) 1.31
Structural and phylogenetic analyses of RGD-CAP/beta ig-h3, a fasciclin-like adhesion protein expressed in chick chondrocytes. Biochim Biophys Acta (1998) 1.26
Purification and structural characterization of transforming growth factor beta induced protein (TGFBIp) from porcine and human corneas. Biochemistry (2004) 1.25
Integrin alpha3beta1, a novel receptor for alpha3(IV) noncollagenous domain and a trans-dominant Inhibitor for integrin alphavbeta3. J Biol Chem (2006) 1.20
RGD peptides released from beta ig-h3, a TGF-beta-induced cell-adhesive molecule, mediate apoptosis. Oncogene (2003) 1.19
Molecular properties of wild-type and mutant betaIG-H3 proteins. Invest Ophthalmol Vis Sci (2002) 1.14
Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res (2004) 1.13
Loss of Betaig-h3 protein is frequent in primary lung carcinoma and related to tumorigenic phenotype in lung cancer cells. Mol Carcinog (2006) 1.12
TGFBI expression is associated with a better response to chemotherapy in NSCLC. Mol Cancer (2010) 1.11
Corneal dystrophy-associated R124H mutation disrupts TGFBI interaction with Periostin and causes mislocalization to the lysosome. J Biol Chem (2009) 1.10
Transforming growth factor-beta-induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells. Int J Cancer (2010) 1.09
Covalent and non-covalent interactions of betaig-h3 with collagen VI. Beta ig-h3 is covalently attached to the amino-terminal region of collagen VI in tissue microfibrils. J Biol Chem (2003) 1.09
Induction and expression of betaig-h3 in pancreatic cancer cells. Biochim Biophys Acta (2002) 1.08
Beta ig-h3 interacts directly with biglycan and decorin, promotes collagen VI aggregation, and participates in ternary complexing with these macromolecules. J Biol Chem (2006) 1.08
Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. Int J Cancer (2008) 1.03
De novo expression of the integrin alpha5beta1 regulates alphavbeta3-mediated adhesion and migration on fibrinogen. J Biol Chem (2003) 1.00
BigH3 protein expression as a marker for breast cancer. Int J Mol Med (2008) 0.98
Expression of alpha(v)beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Hum Pathol (1997) 0.97
Chemotaxis of 3T3 and SV3T3 cells to fibronectin is mediated through the cell-attachment site in fibronectin and a fibronectin cell surface receptor. J Cell Biol (1987) 0.95
Integrin beta3 down-regulates invasive features of ovarian cancer cells in SKOV3 cell subclones. J Cancer Res Clin Oncol (2008) 0.94
One-step purification of recombinant proteins with the 6xHis tag and Ni-NTA resin. Mol Biotechnol (1995) 0.94
Beta ig-h3 induces keratinocyte differentiation via modulation of involucrin and transglutaminase expression through the integrin alpha3beta1 and the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem (2005) 0.91
Integrin cross-talk in endothelial cells is regulated by protein kinase A and protein phosphatase 1. J Biol Chem (2008) 0.86
Cross-talk between integrins and oncogenes modulates chemosensitivity. Mol Pharmacol (2009) 0.86
Optimized expression and refolding of human keratoepithelin in BL21 (DE3). Protein Expr Purif (2004) 0.85
BIGH3 is overexpressed in clear cell renal cell carcinoma. Oncol Rep (2008) 0.83
Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity. Am J Obstet Gynecol (2008) 0.83
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 7.42
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med (2012) 5.69
Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med (2009) 5.63
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol (2010) 5.23
High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol (2007) 4.70
The External RNA Controls Consortium: a progress report. Nat Methods (2005) 4.24
Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell (2007) 3.89
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings. Transfusion (2005) 3.08
Sizing up miRNAs as cancer genes. Nat Med (2005) 2.48
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol (2013) 2.48
A consensus prognostic gene expression classifier for ER positive breast cancer. Genome Biol (2006) 2.17
Chromosomal instability determines taxane response. Proc Natl Acad Sci U S A (2009) 2.12
A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. Oncogene (2005) 2.05
The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell (2007) 2.05
High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer (2007) 1.65
The pitfalls of platform comparison: DNA copy number array technologies assessed. BMC Genomics (2009) 1.55
Frequent recovery and broad genotype 2 diversity characterize hepatitis C virus infection in Ghana, West Africa. J Virol (2003) 1.50
Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol (2011) 1.47
Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer. Hum Mol Genet (2008) 1.47
Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression. Gut (2010) 1.44
Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes. J Pathol (2012) 1.41
Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics (2006) 1.39
Constitutive p38HOG mitogen-activated protein kinase activation induces permanent cell cycle arrest and senescence. Cancer Res (2002) 1.37
A variational Bayesian mixture modelling framework for cluster analysis of gene-expression data. Bioinformatics (2005) 1.36
Multiplex real-time quantitative RT-PCR assay for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1. J Virol Methods (2004) 1.33
BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines. Cancer Res (2007) 1.33
The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer. J Pathol (2012) 1.24
Advanced ovarian cancer: multiparametric MR imaging demonstrates response- and metastasis-specific effects. Radiology (2012) 1.18
Novel conserved elements upstream of the H19 gene are transcribed and act as mesodermal enhancers. Development (2002) 1.13
Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier. Genome Biol (2014) 1.11
Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer. Int J Radiat Oncol Biol Phys (2008) 1.10
Microarrays and breast cancer clinical studies: forgetting what we have not yet learnt. Breast Cancer Res (2005) 1.10
The specificity of the FOXL2 c.402C>G somatic mutation: a survey of solid tumors. PLoS One (2009) 1.07
Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Res (2002) 1.04
A metadata approach for clinical data management in translational genomics studies in breast cancer. BMC Med Genomics (2009) 1.01
Expression microarray reproducibility is improved by optimising purification steps in RNA amplification and labelling. BMC Genomics (2004) 1.01
Molecular characterization of occult hepatitis B virus in genotype E-infected subjects. J Gen Virol (2008) 1.01
Tissue banking of diagnostic lung cancer biopsies for extraction of high quality RNA. J Thorac Oncol (2010) 1.00
MMASS: an optimized array-based method for assessing CpG island methylation. Nucleic Acids Res (2006) 1.00
Boosting Wnt activity during colorectal cancer progression through selective hypermethylation of Wnt signaling antagonists. BMC Cancer (2014) 0.98
Microarray segmentation methods significantly influence data precision. Nucleic Acids Res (2004) 0.95
Apparent diffusion coefficient and vascular signal fraction measurements with magnetic resonance imaging: feasibility in metastatic ovarian cancer at 3 Tesla: technical development. Eur Radiol (2009) 0.94
Genomic analysis of the 8p11-12 amplicon in familial breast cancer. Int J Cancer (2007) 0.90
Dynamic contrast-enhanced MRI in ovarian cancer: Initial experience at 3 tesla in primary and metastatic disease. Magn Reson Med (2010) 0.90
Metabolic characterization of primary and metastatic ovarian cancer by 1H-MRS in vivo at 3T. Magn Reson Med (2009) 0.86
Ovarian clear cell carcinoma--bad endometriosis or bad endometrium? J Pathol (2011) 0.86
Metabolic consequences of p300 gene deletion in human colon cancer cells. Cancer Res (2006) 0.85
Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer. Breast Cancer Res (2008) 0.83
Structural analysis of the genome of breast cancer cell line ZR-75-30 identifies twelve expressed fusion genes. BMC Genomics (2012) 0.83
Evaluation of a transcription-mediated amplification-based HCV and HIV-1 RNA duplex assay for screening individual blood donations: a comparison with a minipool testing system. Transfusion (2003) 0.83
Increased endothelial cell selectivity of triazole-bridged dihalogenated A-ring analogues of combretastatin A-1. Bioorg Med Chem (2012) 0.83
Two novel determinants of etoposide resistance in small cell lung cancer. Cancer Res (2011) 0.82
Total syntheses of subereamollines A and B. Org Biomol Chem (2010) 0.81
Complex stiffness gradient substrates for studying mechanotactic cell migration. Adv Mater (2012) 0.81
Slingshot: a PiggyBac based transposon system for tamoxifen-inducible 'self-inactivating' insertional mutagenesis. Nucleic Acids Res (2010) 0.81
Optimal amounts of fluorescent dye improve expression microarray results in tumor specimens. Mol Biotechnol (2005) 0.81
Molecular pathogenesis of ovarian clear cell carcinoma. Future Oncol (2015) 0.78
A metadata-aware application for remote scoring and exchange of tissue microarray images. BMC Bioinformatics (2013) 0.76
The Xenopus Tgfbi is required for embryogenesis through regulation of canonical Wnt signalling. Dev Biol (2012) 0.75
Stem cells: Anatomy of an ovarian cancer. Nature (2013) 0.75
Intensive cisplatin/oral etoposide for epithelial ovarian cancer: the Cambridge Gynae-Oncology Centre experience: too toxic for relapse? Anticancer Drugs (2016) 0.75
Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation. Gynecol Oncol Case Rep (2013) 0.75